Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.69 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.69 |
| ▸ | HTR3B | O95264 | 1/20 | 0.69 |
| ▸ | HTR5A | P47898 | 1/20 | 0.69 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.69 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.69 |
| ▸ | TERT | O14746 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | S100B | P04271 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594813 | 1.00 | HTR3A (0.69) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL30480097 | 0.98 | HTR3A (0.67) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL4810527 | 0.98 | HTR3A (0.67) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| Formamide SCHEMBL29200631 | 0.88 | HTR3A (0.56) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL12806786 | 0.85 | HTR3A (0.72) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL13561733 | 0.84 | HTR3A (0.51) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL17144739 | 0.84 | HTR3A (0.87) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL4745958 | 0.82 | AKR1C3 (0.69) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL6002185 | 0.82 | HTR3A (1.00) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL3138664 | 0.82 | HTR3A (1.00) | HTR3ASIGMAR1HTR3EHTR3BHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115161672-B | Method for electrochemical synthesis of amino (dithioperoxy) thiocarboxylate compound | 广西师范大学 | 2024-04-16 | — | — | CN | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-112778184-B | Method for arylating alpha position of tertiary amine | 绍兴文理学院 | 2022-05-17 | — | — | CN | disclosed |
| CN-109824465-B | Method for synthesizing amide by amine oxide catalyzed by bipyridine manganese catalyst | 陕西师范大学 | 2022-01-04 | — | — | CN | disclosed |
| CN-112778184-A | Method for arylating alpha position of tertiary amine | 绍兴文理学院 | 2021-05-11 | — | — | CN | disclosed |
| CN-110526848-B | Intermolecular hydrogen transfer initiating cyclic amines β -C (sp)3) Method for synthesizing β -substituted pyrrolidine compound by H functionalization | 青岛农业大学 | 2020-09-08 | — | — | CN | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| CN-104003828-B | The preparation method of copper complex catalytic amine and aromatic nitriles linked reaction under visible light | TIANJIN NORMAL UNIVERSITY (CN) | 2015-08-19 | — | — | CN | disclosed |
| CN-104003828-A | Preparation method of amine and aromaticnitrile coupling reaction catalyzed by copper complex under visible light | UNIV TIANJIN NORMAL | 2014-08-27 | — | — | CN | disclosed |
| US-8212056-B2 | Ligands for transition-metals and methods of use | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-07-03 | — | — | US | disclosed |
| US-8212056-B2 | Ligands for transition-metals and methods of use | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-07-03 | — | — | US | disclosed |
| US-7732473-B2 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | NEUROTUNE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20090326243-A1 | Ligands for transition-metals and methods of use | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-12-31 | — | — | US | disclosed |
| US-20090326243-A1 | Ligands for transition-metals and methods of use | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-12-31 | — | — | US | disclosed |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | HTR3A 3082/4885SIGMAR1 3128/4885HTR3E 3769/4885 |
| US-20090326243-A1 | Ligands for transition-metals and methods of use | PDK4, PDXK, PDK3 | HTR3A 2015/4885SIGMAR1 2588/4885HTR3E 1851/4885 |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | OPRL1, GRIN3B, GRIN3A | HTR3A 130/4885SIGMAR1 62/4885HTR3E 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.